Scholarlink

Purpose <p>Menopause increases cardiometabolic risk via dyslipidaemia, oxidative stress, and low-grade inflammation. Polyphenols may modulate these processes, but human evidence is inconsistent. We investigated the effects of polyphenol supplementation on lipid profile, LDL oxidation, and polyphenol-related gut microbiota metabotypes in postmenopausal women.</p> Methods <p>In the PolyPAUSE randomised, placebo-controlled, crossover trial, 90 mildly hypercholesterolemic, non-medicated postmenopausal women received a daily polyphenol mixture providing ellagitannins+ellagic acid (312.0 ± 30.9&#xa0;mg), resveratrol (133.2 ± 10.1&#xa0;mg), and isoflavones (166.3 ± 27.3&#xa0;mg) for 8 weeks, followed by a 4-week washout and an 8-week placebo period. Serobiochemical and bone-related markers were analysed at hospital laboratories. Apolipoprotein B (ApoB), oxidised LDL (oxLDL), and lipopolysaccharide-binding protein (LBP) were measured by ELISA, and myeloperoxidase activity by spectrophotometry. Gut microbiota metabotypes were classified as urolithin A/B (UMA/UMB), equol producers/non‑producers (EP/ENP), and lunularin producers/non‑producers (LP/LNP) using UPLC‑ESI‑QTOF‑MS.</p> Results <p>Polyphenol supplementation did not affect LBP or bone markers. Total cholesterol (Tchol), LDL-cholesterol (LDLc), and triglycerides (TGs) increased by 7%, 9.5%, and 16%, respectively (<i>p</i> &lt; 0.001) in ~ 80% of completers (<i>n</i> = 78), with age‑related increases. ApoB showed a borderline reduction (<i>p</i> = 0.056), and oxLDL decreased (<i>p</i> &lt; 0.001). Ratios indicating LDL particle quality and oxidative burden (LDLc/ApoB, oxLDL/LDLc, oxLDL/ApoB) improved (<i>p</i> &lt; 0.001) despite higher circulating lipid concentrations. Myeloperoxidase activity showed marginal decreases in the full cohort (<i>p</i> = 0.08) and in LNP (<i>p</i> = 0.06). Metabotyping showed that the strongest oxLDL reduction occurred in EP (65%, <i>p</i> &lt; 0.001) and the UMA + EP+LNP cluster (60%, <i>p</i> &lt; 0.001).</p> Conclusion <p>Polyphenol supplementation increased Tchol, LDLc, and TGs age-dependently, yet improved LDL oxidative quality. The extent of oxLDL reduction depended on metabotypes, supporting precision health approaches to better characterise cardiometabolic responses to polyphenol intake in postmenopausal women.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Polyphenols increase circulating lipids but improve LDL particle quality and reduce LDL oxidation in postmenopausal women: metabotype- and age-dependent effects in a randomised, placebo-controlled crossover trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月29日

查看全文
  • María García-Nicolás,
  • María Paula Jarrín-Orozco,
  • María Romo-Vaquero,
  • Concepción Carrascosa,
  • Francisco Avilés-Plaza,
  • Miriam Martínez-Villanueva,
  • José Antonio Noguera,
  • María Ángeles Ávila-Gálvez,
  • Juan Carlos Espín

摘要

Purpose

Menopause increases cardiometabolic risk via dyslipidaemia, oxidative stress, and low-grade inflammation. Polyphenols may modulate these processes, but human evidence is inconsistent. We investigated the effects of polyphenol supplementation on lipid profile, LDL oxidation, and polyphenol-related gut microbiota metabotypes in postmenopausal women.

Methods

In the PolyPAUSE randomised, placebo-controlled, crossover trial, 90 mildly hypercholesterolemic, non-medicated postmenopausal women received a daily polyphenol mixture providing ellagitannins+ellagic acid (312.0 ± 30.9 mg), resveratrol (133.2 ± 10.1 mg), and isoflavones (166.3 ± 27.3 mg) for 8 weeks, followed by a 4-week washout and an 8-week placebo period. Serobiochemical and bone-related markers were analysed at hospital laboratories. Apolipoprotein B (ApoB), oxidised LDL (oxLDL), and lipopolysaccharide-binding protein (LBP) were measured by ELISA, and myeloperoxidase activity by spectrophotometry. Gut microbiota metabotypes were classified as urolithin A/B (UMA/UMB), equol producers/non‑producers (EP/ENP), and lunularin producers/non‑producers (LP/LNP) using UPLC‑ESI‑QTOF‑MS.

Results

Polyphenol supplementation did not affect LBP or bone markers. Total cholesterol (Tchol), LDL-cholesterol (LDLc), and triglycerides (TGs) increased by 7%, 9.5%, and 16%, respectively (p < 0.001) in ~ 80% of completers (n = 78), with age‑related increases. ApoB showed a borderline reduction (p = 0.056), and oxLDL decreased (p < 0.001). Ratios indicating LDL particle quality and oxidative burden (LDLc/ApoB, oxLDL/LDLc, oxLDL/ApoB) improved (p < 0.001) despite higher circulating lipid concentrations. Myeloperoxidase activity showed marginal decreases in the full cohort (p = 0.08) and in LNP (p = 0.06). Metabotyping showed that the strongest oxLDL reduction occurred in EP (65%, p < 0.001) and the UMA + EP+LNP cluster (60%, p < 0.001).

Conclusion

Polyphenol supplementation increased Tchol, LDLc, and TGs age-dependently, yet improved LDL oxidative quality. The extent of oxLDL reduction depended on metabotypes, supporting precision health approaches to better characterise cardiometabolic responses to polyphenol intake in postmenopausal women.